![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
| Item Type: | Article |
|---|---|
| Title: | The protein deacetylase SIRT2 exerts metabolic control over adaptive β cell proliferation |
| Creators Name: | Wortham, Matthew, Ramms, Bastian, Zeng, Chun, Benthuysen, Jacqueline R., Sai, Somesh, Pollow, Dennis P., Liu, Fenfen, Schlichting, Michael, Harrington, Austin R., Liu, Bradley, Prakash, Thazha P., Pirie, Elaine C., Zhu, Han, Baghdasarian, Siyouneh, Lee, Sean T., Ruthig, Victor A., Wells, Kristen L., Auwerx, Johan, Shirihai, Orian S. and Sander, Maike |
| Abstract: | Selective and controlled expansion of endogenous β-cells has been pursued as a potential therapy for diabetes. Ideally, such therapies would preserve feedback control of β-cell proliferation to avoid excessive β-cell expansion. Here, we identified a regulator of β-cell proliferation whose inactivation results in controlled β-cell expansion: the protein deacetylase Sirtuin 2 (SIRT2). Sirt2 deletion in β-cells of mice increased β-cell proliferation during hyperglycemia with little effect in homeostatic conditions, indicating preservation of feedback control of β-cell mass. SIRT2 restrains proliferation of human islet β-cells, demonstrating conserved SIRT2 function. Analysis of acetylated proteins in islets treated with a SIRT2 inhibitor revealed that SIRT2 deacetylates enzymes involved in oxidative phosphorylation, dampening the adaptive increase in oxygen consumption during hyperglycemia. At the transcriptomic level, Sirt2 inactivation has context-dependent effects on β-cells, with Sirt2 controlling how β-cells interpret hyperglycemia as a stress. Finally, we provide proof-of-principle that systemic administration of a GLP1-coupled Sirt2-targeting antisense oligonucleotide achieves β-cell Sirt2 inactivation and stimulates β-cell proliferation during hyperglycemia. Overall, these studies identify a therapeutic strategy for increasing β-cell mass in diabetes without circumventing feedback control of β-cell proliferation. Future work should test the extent that these findings translate to human β-cells from individuals with and without diabetes. |
| Keywords: | Animals, Mice |
| Source: | Journal of Clinical Investigation |
| ISSN: | 0021-9738 |
| Publisher: | American Society for Clinical Investigation |
| Page Range: | e187020 |
| Date: | 31 July 2025 |
| Official Publication: | https://doi.org/10.1172/JCI187020 |
| PubMed: | View item in PubMed |
| Related to: |
Repository Staff Only: item control page
